Skip to main content
Scorpion Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of STX-478, Its Mutant-Selective PI3Kα Inhibitor for the Treatment of Breast Cancer and Other Solid Tumors
More Info

In The News


STX-478, a mutant-selection PI3Kα inhibitor clinical candidate with a best-in-class-profile

Identification of STX-721, an EGFR exon 20 mutant inhibitor with superior selectivity and a potential best-in-class profile

Discovery and characterization of a PI3KαH1047X mutant selective inhibitor with a best-in-class profile

Press Releases